Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder.

Jakobsson J, Stridsberg M, Zetterberg H, Blennow K, Ekman CJ, Johansson AG, Sellgren C, Landén M.

J Psychiatry Neurosci. 2013 Jul;38(4):E21-6. doi: 10.1503/jpn.120170.

2.

Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis.

Mattsson N, Rüetschi U, Podust VN, Stridsberg M, Li S, Andersen O, Haghighi S, Blennow K, Zetterberg H.

J Neurochem. 2007 Dec;103(5):1932-9. Epub 2007 Oct 22.

3.

Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder.

Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landén M.

Neuropsychopharmacology. 2013 Mar;38(4):664-72. doi: 10.1038/npp.2012.231. Epub 2012 Nov 6.

4.

Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.

Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA.

Biol Psychiatry. 2009 Mar 15;65(6):489-94. doi: 10.1016/j.biopsych.2008.11.010. Epub 2008 Dec 21.

5.

Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Olsson SK, Samuelsson M, Saetre P, Lindström L, Jönsson EG, Nordin C, Engberg G, Erhardt S, Landén M.

J Psychiatry Neurosci. 2010 May;35(3):195-9.

6.

Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.

Jakobsson J, Bjerke M, Ekman CJ, Sellgren C, Johansson AG, Zetterberg H, Blennow K, Landén M.

Neuropsychopharmacology. 2014 Sep;39(10):2349-56. doi: 10.1038/npp.2014.81. Epub 2014 Apr 3.

7.

Mixed depression: a clinical marker of bipolar-II disorder.

Benazzi F.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):267-74. Epub 2005 Jan 28.

PMID:
15694234
8.

Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment.

Marksteiner J, Weiss U, Weis C, Laslop A, Fischer-Colbrie R, Humpel C, Feldon J, Fleischhacker WW.

Neuroscience. 2001;104(2):325-33.

PMID:
11377837
9.

Microscopic particles in two fractions of fresh cerebrospinal fluid in twins with schizophrenia or bipolar disorder and in healthy controls.

Johansson V, Nybom R, Wetterberg L, Hultman CM, Cannon TD, Johansson AG, Ekman CJ, Landén M.

PLoS One. 2012;7(9):e45994. doi: 10.1371/journal.pone.0045994. Epub 2012 Sep 25.

10.

Role of risperidone in bipolar II: an open 6-month study.

Vieta E, Gastó C, Colom F, Reinares M, Martínez-Arán A, Benabarre A, Akiskal HS.

J Affect Disord. 2001 Dec;67(1-3):213-9.

PMID:
11869771
11.

Bipolar II disorder : epidemiology, diagnosis and management.

Benazzi F.

CNS Drugs. 2007;21(9):727-40. Review.

PMID:
17696573
12.

Molecular characterization of immunoreactivities of peptides derived from chromogranin A (GE-25) and from secretogranin II (secretoneurin) in human and bovine cerebrospinal fluid.

Kirchmair R, Benzer A, Troger J, Miller C, Marksteiner J, Saria A, Gasser RW, Hogue-Angeletti R, Fischer-Colbrie R, Winkler H.

Neuroscience. 1994 Dec;63(4):1179-87.

PMID:
7535395
13.

[Who are patients suffering from bipolar disorders in France? The TEMPPO survey: patients' sociodemographic and clinical characteristics data].

de Carvalho W, Nuss P, Blin P, Arnaud R, Filipovics A, Loze JY, Dillenschneider A.

Encephale. 2012 Jun;38(3):211-23. doi: 10.1016/j.encep.2012.04.007. Epub 2012 Jun 5. French.

PMID:
22726409
14.

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.

Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Review.

PMID:
18501566
15.

CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).

Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, Benzer A, Winkler H.

Biol Psychiatry. 1996 Jun 1;39(11):911-8.

PMID:
9162202
16.

Metabolic alterations in medication-free patients with bipolar disorder: a 3T CSF-corrected magnetic resonance spectroscopic imaging study.

Port JD, Unal SS, Mrazek DA, Marcus SM.

Psychiatry Res. 2008 Feb 28;162(2):113-21. doi: 10.1016/j.pscychresns.2007.08.004. Epub 2007 Dec 31. Erratum in: Psychiatry Res. 2008 Oct 30;164(1):95.

PMID:
18164911
17.

Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder.

Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, Landén M, Engberg G.

J Psychiatry Neurosci. 2011 Mar;36(2):114-8. doi: 10.1503/jpn.100080.

18.

Screening for bipolar disorder in a Spanish sample of outpatients with current major depressive episode.

Tafalla M, Sanchez-Moreno J, Diez T, Vieta E.

J Affect Disord. 2009 Apr;114(1-3):299-304. doi: 10.1016/j.jad.2008.06.025. Epub 2008 Aug 13.

PMID:
18701169
19.

Cerebrospinal fluid total protein in patients with affective disorders.

Pazzaglia PJ, Post RM, Rubinow D, Kling MA, Huggins TS, Sunderland T.

Psychiatry Res. 1995 Aug 28;57(3):259-66.

PMID:
7501736
20.

Subsyndromal depressive symptoms in patients with bipolar and unipolar disorder during clinical remission.

Vieta E, Sánchez-Moreno J, Lahuerta J, Zaragoza S; EDHIPO Group (Hypomania Detection Study Group).

J Affect Disord. 2008 Apr;107(1-3):169-74. Epub 2007 Sep 17.

PMID:
17870184
Items per page

Supplemental Content

Write to the Help Desk